FXAMEDIUM SIGNALFINANCIAL10-K

FXA's financial performance declined across key metrics while the trust's expense structure improved, with sponsor fees rising and interest income now exceeding expenses.

The shift from expenses exceeding interest income to a "significant margin" of positive spread indicates improved operational efficiency for the currency trust. However, the broad-based decline in financial performance metrics suggests challenging market conditions for Australian dollar exposure during the period.

Comparing 2026-03-02 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

FXA experienced a comprehensive decline in financial performance, with net income, revenue, and operating cash flow all falling by double-digit percentages. Total assets grew meaningfully to $89.3M while cash holdings decreased to $141.8M, indicating portfolio repositioning. The overall picture reflects a challenging period for the Australian dollar trust, though improved expense management provides some operational bright spots.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+38.5%
$64.5M$89.3M

Asset base grew 38.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-21.3%
$51K$40K

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-20.7%
$178.8M$141.8M

Cash decreased 20.7% — monitor burn rate and upcoming capital needs.

Operating Cash Flow
Cash Flow
-19%
$1.1M$893K

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Net Income
P&L
-18.5%
$1.1M$879K

Net income declined 18.5% — review whether driven by operations, interest costs, or non-recurring items.

Dividends Paid
Cash Flow
-17.2%
$1.1M$906K

Dividend reduced 17.2% — monitor management commentary on capital allocation priorities.

Current Assets
Balance Sheet
-15%
$142.0M$120.6M

Current assets declined 15% — monitor working capital adequacy and short-term liquidity.

Revenue
P&L
-12.7%
$1.4M$1.2M

Revenue softened 12.7% — monitor whether this is cyclical or structural.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-26
ADDED
The Trust incurred $305,445 for the year ended December 31, 2025 in Sponsor s fees.
The amount of interest earned by the Trust has not always exceeded expenses.
That was not the case in 2025, when interest income exceeded expenses by a significant margin; but, when expenses exceed interest income, the Trustee needs to withdraw Australian Dollars from the Trust to pay the excess expenses.
International Armed Conflicts May Result in Volatility in Currency Prices that Could Adversely Affect the Fund s Performance.
As a result of increasingly interconnected global economies and financial markets, armed conflict between countries or in a geographic region, including related geopolitical tensions or emergency measures, may impact the value of the currencies held by the Fund.
+7 more — sign up free →
REMOVED
The Trust incurred $277,952 for the year ended December 31, 2024 in Sponsor s fees.
Recently, the amount of interest earned by the Trust has not exceeded the Trust s expenses; accordingly, the Trustee has been required to withdraw Australian Dollars from the Trust to pay these excess expenses.
International Armed Conflicts May Result in Volatility in Currency Prices that Could Adversely Affect the Fund's Performance.
As a result of increasingly interconnected global economies and financial markets, armed conflict between countries or in a geographic region, for example the current conflicts between Russia and Ukraine in Europe and Hamas and Israel in the Middle East, may impact the value of the currencies held by the Fund.
Pandemics and other public health emergencies could disrupt the global economy and adversely impact the Trust's performance.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →